On the other hand, no targeted treatments against the main alterations identified T-ALL/LBL are currently available in the clinical setting and since the approval of nelarabine in 2005 no pharmacological inhibitors have been approved for relapsed/refractory (R/R) T-ALL/LBL patients. All this highlights two unmet needs: 1) a more refined stratification of T-ALL/LBL patients according to their potential risk, which would lead to improved cure rates and reduced toxicity; and 2) the development of targeted treatments against the main alterations affecting T-ALL/LBL patients, which would contribute to lowering chemotherapy doses to avoid late effects and would offer a therapeutic option for R/R patients. Our group is trying to contribute to solve these two issues. Using genomic, transcriptomic and clinical data from patients, therapy prioritization algorithms based on the patient’s omics characteristics, together with molecular approaches to validate our hypotheses, we explore the genetic and molecular alterations in patients to identify molecular markers that are predictive of poor response to treatment and that can be obtained at diagnosis. In addition, we aim to identify potential therapeutic targets amenable to pharmacological intervention. As members of Fundación Jiménez Díaz Health Research Institute, our research involves the active participation of our colleagues from the Haematology and Pathologic Anatomy services. For years, we have been working closely together to assign a clinical significance to our molecular results. With our research, we expect to contribute to a better clinical management of this disease, with a better identification of high-risk patients to guide their treatment, and with an enhanced efficacy of current therapies in a relevant fraction of patients whose targeted treatment is nowadays an unmet need. Ultimately, this would contribute to increase the cure rates for T-ALL/LBL patients.